Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care
An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly...
Gespeichert in:
| Veröffentlicht in: | Cleveland Clinic journal of medicine 2024-06, Vol.91 (6), p.361-371 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 6 |
| container_start_page | 361 |
| container_title | Cleveland Clinic journal of medicine |
| container_volume | 91 |
| creator | Wiser, Amy L |
| description | An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access. |
| doi_str_mv | 10.3949/ccjm.91a.23079 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3064580875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3064580875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-a8041ea2e59e7721d8668764c9e7cb35218e8ac56d08e29e427a7d0af5e88cd13</originalsourceid><addsrcrecordid>eNo9kDtPwzAUhS0EoqWwMqKMLAl-xLHNhiqglZBACLparnMDqZK42Alq_z0uLUz3dc7R1YfQJcEZU7m6sXbVZoqYjDIs1BEaE8VUSmWhjtEYS0VSQjgeobMQVhhTTqg6RSMmZZRjMkaLFw-wWbsweEjW3q0_t43Z1CGpnI8zfEPX191HMpsvkrqrwPa1626TVzfE9c5h4sZCvMW-bo3fJtZ4OEcnlWkCXBzqBL0_3L9NZ-nT8-N8eveUWqpwnxqJcwKGAlcgBCWlLAopitzG0S4Zp0SCNJYXJZZAFeRUGFFiU3GQ0paETdD1Pje-_jVA6HVbBwtNYzpwQ9AMFzmXWAoepdlear0LwUOlDw9rgvWOpd6x1JGl_mUZDVeH7GHZQvkv_4PHfgAMUHEv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3064580875</pqid></control><display><type>article</type><title>Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Wiser, Amy L</creator><creatorcontrib>Wiser, Amy L</creatorcontrib><description>An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access.</description><identifier>ISSN: 0891-1150</identifier><identifier>EISSN: 1939-2869</identifier><identifier>DOI: 10.3949/ccjm.91a.23079</identifier><identifier>PMID: 38830701</identifier><language>eng</language><publisher>United States</publisher><subject>Anti-HIV Agents - administration & dosage ; Anti-HIV Agents - therapeutic use ; Emtricitabine - administration & dosage ; Emtricitabine - therapeutic use ; HIV Infections - prevention & control ; Humans ; Male ; Pre-Exposure Prophylaxis - methods ; Primary Health Care ; Tenofovir - administration & dosage ; Tenofovir - therapeutic use</subject><ispartof>Cleveland Clinic journal of medicine, 2024-06, Vol.91 (6), p.361-371</ispartof><rights>Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38830701$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wiser, Amy L</creatorcontrib><title>Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care</title><title>Cleveland Clinic journal of medicine</title><addtitle>Cleve Clin J Med</addtitle><description>An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access.</description><subject>Anti-HIV Agents - administration & dosage</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Emtricitabine - administration & dosage</subject><subject>Emtricitabine - therapeutic use</subject><subject>HIV Infections - prevention & control</subject><subject>Humans</subject><subject>Male</subject><subject>Pre-Exposure Prophylaxis - methods</subject><subject>Primary Health Care</subject><subject>Tenofovir - administration & dosage</subject><subject>Tenofovir - therapeutic use</subject><issn>0891-1150</issn><issn>1939-2869</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kDtPwzAUhS0EoqWwMqKMLAl-xLHNhiqglZBACLparnMDqZK42Alq_z0uLUz3dc7R1YfQJcEZU7m6sXbVZoqYjDIs1BEaE8VUSmWhjtEYS0VSQjgeobMQVhhTTqg6RSMmZZRjMkaLFw-wWbsweEjW3q0_t43Z1CGpnI8zfEPX191HMpsvkrqrwPa1626TVzfE9c5h4sZCvMW-bo3fJtZ4OEcnlWkCXBzqBL0_3L9NZ-nT8-N8eveUWqpwnxqJcwKGAlcgBCWlLAopitzG0S4Zp0SCNJYXJZZAFeRUGFFiU3GQ0paETdD1Pje-_jVA6HVbBwtNYzpwQ9AMFzmXWAoepdlear0LwUOlDw9rgvWOpd6x1JGl_mUZDVeH7GHZQvkv_4PHfgAMUHEv</recordid><startdate>20240603</startdate><enddate>20240603</enddate><creator>Wiser, Amy L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240603</creationdate><title>Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care</title><author>Wiser, Amy L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-a8041ea2e59e7721d8668764c9e7cb35218e8ac56d08e29e427a7d0af5e88cd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-HIV Agents - administration & dosage</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Emtricitabine - administration & dosage</topic><topic>Emtricitabine - therapeutic use</topic><topic>HIV Infections - prevention & control</topic><topic>Humans</topic><topic>Male</topic><topic>Pre-Exposure Prophylaxis - methods</topic><topic>Primary Health Care</topic><topic>Tenofovir - administration & dosage</topic><topic>Tenofovir - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wiser, Amy L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cleveland Clinic journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wiser, Amy L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care</atitle><jtitle>Cleveland Clinic journal of medicine</jtitle><addtitle>Cleve Clin J Med</addtitle><date>2024-06-03</date><risdate>2024</risdate><volume>91</volume><issue>6</issue><spage>361</spage><epage>371</epage><pages>361-371</pages><issn>0891-1150</issn><eissn>1939-2869</eissn><abstract>An estimated 1.2 million people in the United States have human immunodeficiency virus (HIV) infection per US Centers for Disease Control and Prevention 2021 data. The highest risk of HIV transmission occurs during injection drug use with needle sharing and during sexual activity, most significantly in condomless, receptive anal intercourse. Preexposure prophylaxis (PrEP) for the prevention of HIV infection is part of a larger biobehavioral strategy that uses antiretroviral medication, an oral formulation taken daily or during anticipated exposure events, or an injectable formulation administered every 8 weeks. PrEP consists of 3 possible regimens: emtricitabine/tenofovir disoproxil fumarate, emtricitabine/tenofovir alafenamide, or injectable cabotegravir. Primary care clinicians are strategically positioned to provide PrEP education and access.</abstract><cop>United States</cop><pmid>38830701</pmid><doi>10.3949/ccjm.91a.23079</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0891-1150 |
| ispartof | Cleveland Clinic journal of medicine, 2024-06, Vol.91 (6), p.361-371 |
| issn | 0891-1150 1939-2869 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3064580875 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Anti-HIV Agents - administration & dosage Anti-HIV Agents - therapeutic use Emtricitabine - administration & dosage Emtricitabine - therapeutic use HIV Infections - prevention & control Humans Male Pre-Exposure Prophylaxis - methods Primary Health Care Tenofovir - administration & dosage Tenofovir - therapeutic use |
| title | Preexposure prophylaxis for preventing HIV infection: Routine practice in primary care |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T07%3A50%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Preexposure%20prophylaxis%20for%20preventing%20HIV%20infection:%20Routine%20practice%20in%20primary%20care&rft.jtitle=Cleveland%20Clinic%20journal%20of%20medicine&rft.au=Wiser,%20Amy%20L&rft.date=2024-06-03&rft.volume=91&rft.issue=6&rft.spage=361&rft.epage=371&rft.pages=361-371&rft.issn=0891-1150&rft.eissn=1939-2869&rft_id=info:doi/10.3949/ccjm.91a.23079&rft_dat=%3Cproquest_cross%3E3064580875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3064580875&rft_id=info:pmid/38830701&rfr_iscdi=true |